Evidence map›Paper›PMID 33502902›Full record

ReviewAnnual review of medicine2021

Advances in Chronic Obstructive Pulmonary Disease.

Michael C Ferrera, Wassim W Labaki, MeiLan K Han

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annual review of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07543601 (Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention), which is not on this map. Cited by 99 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 6 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07543601 narecruitingnot on this mapstarted 2026, after this paper: background citation

Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention

TypeinterventionalSponsorDitte Krag-HansenRan2026 to 2027Enrolled280ConditionsCOPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis), Lung Neoplasm Malignant, Lung CarcinomaArmsTailored COPD consultations
3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 6 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Pre-COPD: Impact on prevention, detection, and treatment.Presse medicale (Paris, France : 1983) · 2026
    Review
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael C FerreraDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA; email: mrking@med.umich.edu, miferrer@med.umich.edu, wlabaki@med.umich.edu.
Wassim W LabakiDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA; email: mrking@med.umich.edu, miferrer@med.umich.edu, wlabaki@med.umich.edu.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA; email: mrking@med.umich.edu, miferrer@med.umich.edu, wlabaki@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

Defining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2M
Leveraging Serum Metabolomics to Understand Clinical Phenotypes in COPDK23HL151751 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LABAKI, WASSIM W · 2020 to 2024
$875k
NHLBI NIH HHS K23 HL151751NHLBI NIH HHS K24 HL138188
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20 years with the introduction of new oral and inhaled medications as well as novel surgical and bronchoscopic procedures. This article summarizes some of the recent advances in our understanding of disease pathogenesis and treatment paradigms.

Indexed as

Global HealthHumansLungMorbidityPulmonary Disease, Chronic ObstructiveRespiratory Function TestsSurvival Ratechronic bronchitisCOPDemphysemalung function

Identifiers

PMID33502902
PMCPMC8011854
OpenAlexW3121853105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.